Evidence map›Paper›PMID 36986828›Full record

ArticlePharmaceutics2023

Dose-Effect Determination of a Neuroprotector Fraction Standardized in Coumarins of

Anislada Santibáñez, Maribel Herrera-Ruiz, Manasés González-Cortazar, Pilar Nicasio-Torres, Ashutosh Sharma, Enrique Jiménez-Ferrer

Open access · goldFull text read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anislada SantibáñezCentro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social, Argentina No. 1 Col Centro, Xochitepec 62790, Morelos, Mexico.ORCID 0000-0001-6374-3651
Maribel Herrera-RuizCentro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social, Argentina No. 1 Col Centro, Xochitepec 62790, Morelos, Mexico.ORCID 0000-0001-9056-3568
Manasés González-CortazarCentro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social, Argentina No. 1 Col Centro, Xochitepec 62790, Morelos, Mexico.ORCID 0000-0002-3693-1670
Pilar Nicasio-TorresCentro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social, Argentina No. 1 Col Centro, Xochitepec 62790, Morelos, Mexico.ORCID 0000-0003-2045-6665
Ashutosh SharmaSchool of Engineering and Sciences, Tecnologico de Monterrey, Plant Innovation Lab, Av. Epigmenio González No. 500, San Pablo 76130, Queretaro, Mexico.ORCID 0000-0002-9000-1378
Enrique Jiménez-FerrerCentro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social, Argentina No. 1 Col Centro, Xochitepec 62790, Morelos, Mexico.ORCID 0000-0002-0783-8274
Mexican Social Security Institute · MXTecnológico de Monterrey · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegeneration has been associated with chronic inflammation states in the brain. For this reason, attention has been directed to drugs indicated as anti-inflammatory as possible therapies for the treatment of said conditions.

Indexed as

7-O-prenylscopoletin (PE)7-O-prenylumbelliferone (PU)dimethylfraxetin (DF)herniarin (HR)neuroprotectorpharmacodynamicspharmacokineticsscoparone (SC)

Identifiers

PMID36986828
PMCPMC10051064
OpenAlexW4327740188

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read46
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.